Search hospitals > California > Truckee
Gene Upshaw Memorial Tahoe Forest Cancer Center
Claim this profileTruckee, California 96161
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
128 reported clinical trials
16 medical researchers
Summary
Gene Upshaw Memorial Tahoe Forest Cancer Center is a medical facility located in Truckee, California. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Gene Upshaw Memorial Tahoe Forest Cancer Center is involved with conducting 128 clinical trials across 244 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, David R. Gandara, Aaron Rosenberg, and Richard J. Bold.Area of expertise
1Lung Cancer
Global LeaderStage II
Stage IV
Stage I
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Edward J. KimUniversity of California Davis Comprehensive Cancer Center2 years of reported clinical research
Studies Pancreatic Cancer
Studies Liver Cancer
33 reported clinical trials
70 drugs studied
David R. GandaraUniversity of California Davis Comprehensive Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
22 drugs studied
Aaron RosenbergUniversity of California Davis Comprehensive Cancer Center1 year of reported clinical research
Studies Multiple Myeloma
Studies Plasma Cell Neoplasms
12 reported clinical trials
21 drugs studied
Richard J. BoldGene Upshaw Memorial Tahoe Forest Cancer Center4 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
12 reported clinical trials
35 drugs studied
Clinical Trials running at Gene Upshaw Memorial Tahoe Forest Cancer Center
Lung Cancer
Breast Cancer
Breast cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Multiple Myeloma
ALK Gene Rearrangement
Colon Cancer
Lung Adenocarcinoma
Prostate Adenocarcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Cemiplimab
for Non-Small Cell Lung Cancer
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 2 & 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Gene Upshaw Memorial Tahoe Forest Cancer Center?
Gene Upshaw Memorial Tahoe Forest Cancer Center is a medical facility located in Truckee, California. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Gene Upshaw Memorial Tahoe Forest Cancer Center is involved with conducting 128 clinical trials across 244 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, David R. Gandara, Aaron Rosenberg, and Richard J. Bold.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.